Polyneuron announces the completion of a CHF 3.1 million seed financing, following the receipt of a second tranche. Furthermore, the company’s management team and the board of directors have been strengthened. Press release
In other news
-
General
Polyneuron and University of Basel awarded grant of CHF 1.2 M to advance novel treatments to support ABO-Incompatible transplantsPolyneuron is proud to announce that – together with the… [read on]
-
Uncategorized
Polyneuron appoints Aled Williams as chief business officerWe are extremely pleased to welcome Aled Williams to Polyneuron… [read on]
-
General
Polyneuron extends Series A to CHF 36.5 millionPolyneuron announces a CHF 14 million extension of the Series… [read on]
-
General
Polyneuron's PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG NeuropathyPolyneuron is proud to announce that the U.S. Food and… [read on]
-
General
Polyneuron receives approval to begin clinical study with PN-1007 in anti-MAG neuropathyWe are very proud to have received our… [read on]
-
General
Polyneuron announces appointment of chief medical officerWe are extremely pleased to welcome Dr Debra Barker to… [read on]
-
General
Polyneuron annouces appointment of new ChairmanPolyneuron announces the appointment of Ben Machielse as Chairman of… [read on]
-
Financing
Polyneuron raises CHF 22.5 million in a major Series A financingPolyneuron raises CHF 22.5 million in an oversubscribed… [read on]